Companies are targeting poison exons embedded in mRNA transcripts as a strategy to restore wild-type protein abundance and cell fitness in severe pediatric epilepsy and other genetic diseases.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. A new class of mRNA drugs targets poison exons. Nat Biotechnol 42, 1159–1161 (2024). https://doi.org/10.1038/s41587-024-02355-4
Published:
Issue date:
DOI: https://doi.org/10.1038/s41587-024-02355-4